439 related articles for article (PubMed ID: 29284590)
1. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
Ezziddin S; Lauschke H; Schaefers M; Meyer C; van Essen M; Biersack HJ; Kwekkeboom DJ; Ahmadzadehfar H
Clin Nucl Med; 2012 Jan; 37(1):102-4. PubMed ID: 22157044
[No Abstract] [Full Text] [Related]
3. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
10. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
11. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
[TBL] [Abstract][Full Text] [Related]
12. Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2018 Sep; 43(9):676-678. PubMed ID: 30080185
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
14. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT).
Schiavo Lena M; Partelli S; Castelli P; Andreasi V; Smart CE; Pisa E; Bartolomei M; Bertani E; Zamboni G; Falconi M; Doglioni C
Endocr Pathol; 2020 Jun; 31(2):119-131. PubMed ID: 32361926
[TBL] [Abstract][Full Text] [Related]
16. Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Zagar TM; White RR; Willett CG; Tyler DS; Papavassiliou P; Papalezova KT; Guy CD; Broadwater G; Clough RW; Czito BG
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1126-31. PubMed ID: 22270161
[TBL] [Abstract][Full Text] [Related]
17. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
20. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]